Introduction en Bourse de Medtech sur Euronext

Back

Paris, 28 November 2013 – Medtech, a world-class player in surgical robotics used in central nervous system procedures, today celebrated its listing in compartment C of the Paris market operated by Euronext N.V. EnterNext, the NYSE Euronext subsidiary dedicated to promoting and growing the SME market, welcomed the new company, which will now benefit from its products and services.

Medtech specialises in designing, producing and marketing innovative robotic systems that assist neurosurgeons in cranial and spinal procedures. Using robots made entirely in France, the company has launched ROSA™, a ground-breaking solution designed to give surgeons new options for minimally invasive surgery. Unparalleled precision and ease of use are built into this new technology platform, whose leading-edge technology has been widely recognised and is protected by several international patent families.

Buoyed by growing demand from healthcare professionals, Medtech was elected Frost & Sullivan’s European Company of the Year for surgical robotics in 2013.

Medtech (ticker symbol: ROSA) was listed through the admission to trading of 1,647,920 shares making up the company’s equity and 740,741 new shares issued as part of a Global Offering1 , including full exercise of the extension clause and over-allocation option.

The admission and issue price of Medtech shares was set at €27 per share. Market capitalisation on the day of listing came to around €64.5 million. The total amount raised was around €20 million.

“We are delighted to welcome Medtech to our European market,”said EnterNext CEO Eric Forest. “And we are convinced that this listing will give the company fresh momentum as it expands in France and on international markets. Our entire EnterNext team will be working with Medtech to help it achieve its ambitious goals,” he added.

Bertin Nahum, Chairman & CEO and founder of Medtech, said: “I would like to thank all of the institutional and individual shareholders that have joined us, as well as all of our staff and partners, for their contributions to the success of our IPO. We will be going all out to ensure that our market performance lives up to the confidence you have demonstrated today.”

To celebrate Medtech’s listing, Bertin Nahum rang the Opening Bell for Euronext’s European market. He was accompanied by Medtech executives, advisors, and financial and legal affairs partners, along with the EnterNext team.


1 The Global Offering was made up of a Public Offering in France in the form of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With close to 2,000 listed issuers and around €5.8 trillion in market capitalisation as of end June 2022, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2022, Euronext N.V. - All rights reserved.